Rossari Biotech Ltd - 543213 - Statement Of Investor Complaints For The Quarter Ended September 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Ms Parul GuptaDesignation :- Company Secretary and Compliance Officer Rossari Biotech Ltd - 543213 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Compliance Certificate under Regulation 74 (5) of SEBI (Depository and Participants) Regulations, 2018 for the quarter ended September 30, 2022. Rossari Biotech Ltd - 543213 - Closure of Trading Window
Intimation of Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Analysts/Institutional Investor Meet/Con. Call Updates Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Updates on Acquisition
Update on Acquisition of Tristar Intermediaries Private Limited Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Updates on Acquisition
Update on Acquisition of Unitop Chemicals Private Limited Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Analysts/Institutional Investor Meet/Con. Call Updates Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Intimation of Transcript of the Q1 & FY23 Earnings Conference Call held on August 09, 2022
Results Earnings Call for Q1FY23 of Rossari Biotech
Conference Call with Rossari Biotech Management and Analysts on Q1FY23 Performance and Outlook. Listen to the full earnings transcript. Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio Recording of Earnings Conference call for Q1 & FY23